BioAtla 10-Q: $0.6M Cash Left, Going Concern Reaffirmed, $4.9M Impairment
BCAB sits 46% above its 52-week low of $1.07.
Summary
BioAtla closed Q3 with only $0.6 million in cash and reaffirmed going-concern doubt, while booking a $4.9 million lease impairment and taking a $400,000 related-party note from a CEO-controlled entity.
Key Events · Earnings and Guidance · BCAB
-
Cash Drops to $0.6 Million
Cash and cash equivalents fell to $576 thousand at September 30, 2026 from $7.1 million at December 31, 2025, while accounts payable and accrued expenses rose to $18.9 million.
-
Going Concern Doubt Reaffirmed
Management concluded current cash is not sufficient to fund operations for at least twelve months from the issuance date of these financial statements, and the company may be forced to wind down if it cannot raise capital or complete a strategic transaction.
-
$4.9 Million Lease Impairment
The company wrote off its operating lease right-of-use asset entirely, recording a $4.9 million impairment tied to the sustained stock price decline and the September 2026 Nasdaq delisting.
-
Related-Party $400,000 Note
On November 10, 2026 BioAtla issued a $400,000 promissory note bearing 10% simple interest to Inversagen AI LLC, whose managers include CEO Jay Short and his spouse; principal is due on demand after November 10, 2027 and is not convertible.
Analysis · BCAB · Life Sciences
BioAtla ended September with just $0.6 million of cash against $18.9 million of accounts payable and accrued expenses, and management again concluded there is substantial doubt about the company's ability to continue as a going concern for at least a year. The quarter's $7.9 million net loss was flattered by a $4.9 million non-cash write-down of the lease right-of-use asset and a $0.5 million warrant mark-to-market gain, so the underlying cash burn of $6.7 million over nine months is the number that matters. The only lifelines are the $40 million Yorkville standby equity line, which is capped by trading volume on the OTCQB and by a 4.99% ownership blocker, and a $400,000 promissory note the company just took from a related party controlled by the CEO and his spouse. With the stock delisted to the OTCQB and a strategic review still running, the equity is a leveraged bet on a sale or licensing deal before cash runs out.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCAB was trading at $1.56 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $1.07 to $3,575.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.